Sutro Biopharma (STRO) Gets a Buy Rating from Cowen & Co.

In a report released today, Boris Peaker from Cowen & Co. maintained a Buy rating on Sutro Biopharma (STROResearch Report). The company’s shares closed last Monday at $11.38.

According to TipRanks.com, Peaker has currently no stars on a ranking scale of 0-5 stars, with an average return of -2.1% and a 38.7% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Pacira Pharmaceuticals, and Emergent Biosolutions.

Currently, the analyst consensus on Sutro Biopharma is a Strong Buy with an average price target of $17.00, which is a 55.3% upside from current levels. In a report issued on October 30, H.C. Wainwright also maintained a Buy rating on the stock with a $18.00 price target.

See today’s analyst top recommended stocks >>

Based on Sutro Biopharma’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $13.79 million. In comparison, last year the company had a GAAP net loss of $10.24 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sutro Biopharma Inc. engages in the drug discovery, development and manufacturing of pharmaceutical products. Its products technologies include XpressCF, anti-body drug conjugates, bispecifics & engineered antibodies and cGMP facility. The company was founded by James R. Swartz and Sutanto Widjaja in June 2003 and is headquartered in South San Francisco, CA.